4.7 Article

eIF3c: A potential therapeutic target for cancer

Journal

CANCER LETTERS
Volume 336, Issue 1, Pages 158-166

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2013.04.026

Keywords

elF3; elF3c; Translation; RNAi; Lipid-based nanoparticles

Categories

Funding

  1. Lewis Trust
  2. Leona M. and Harry B. Helmsley Nanotechnology Research Fund

Ask authors/readers for more resources

Cancer cells are rapidly evolving due to their unstable genome, which contributes to the development of new cancer clones with different gene expression profile (GEP). Manipulating the expression of the genes vital for the progression of the disease is essential to overcome its heterogeneity. However, targeting overexpressed genes, retrieved from GEP analysis, would be efficient for a specific kind of a malignancy. Alternatively, manipulating the expression of genes that are part of a fundamental mechanism in the cell would be effective against a wide range of malignancies. To test this hypothesis we characterized, using RNAi approaches, the therapeutic potential of the housekeeping eIF3c gene in five different cancer cell lines NCI-ADR/RES (NAR), HeLa, MCF7, HCT116 and B16F10. elF3c is one of the core subunit of the eukaiyote translation initiation factor (elF) 3 complex, which has a crucial role in the translation initiation process. In this study, we demonstrated that eIF3c is vital to translation initiation in vivo, as its down-regulation decreases the global protein synthesis and causes a polysome run-off. In addition, reducing the expression of eIF3c mediates G(0)/G(1) or G(2)/M arrest in a tissue dependent manner, which leads to a reduction in cell proliferation and eventually to cell death. Moreover, we demonstrated the efficiency of the hyaluronan (HA)-coated lipid-based nanoparticles (LNPs) platform to deliver eIF3c-siRNAs to mouse melanoma cells. Taking together, our results emphasize the importance of seeking ubiquitously expressed housekeeping genes such as eIF3c rather than tumor associated overexpressed genes as therapeutic targets for the heterogeneous malignancies. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available